Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Multi-centre modified Delphi exercise to identify candidate items for classifying early-stage symptomatic knee osteoarthritis.
Osteoarthritis Cartilage
January 2025
Department of Medicine, University of Toronto, Toronto, Canada; Research and Innovation Institute, Women's College Hospital, Toronto, Canada. Electronic address:
Objective: To generate a list of candidate items potentially useful for discriminating individuals with Early-stage Symptomatic Knee Osteoarthritis (EsSKOA) from those with other conditions and from established osteoarthritis (OA), and to reduce this list based on expert consensus.
Design: We conducted a three-round online international modified Delphi exercise with OA clinicians and researchers ("OA experts"). In Round 1, participants reviewed 84 candidate items and nominated additional item(s) potentially useful for EsSKOA classification; those nominated by ≥3 participants were added.
The influence of age, gender and pharmacogenetic profiles on the perspective on medicines in the German EMPAR study.
PLoS One
October 2024
Research Division, Federal Institute for Drugs and Medical Devices, Bonn, North Rhine-Westphalia, Germany.
Background: Pharmacogenetic testing in routine care could provide benefits for patients, doctors and statutory health insurances. Therefore, the aim of the retrospective, observational study Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung (EMPAR) was to analyze the relationship between pharmacogenetic profiles, the risk of adverse drug reactions, and patients' perceptions of drug therapy in 10748 adult (≥18 years) participants in Germany.
Methods: A questionnaire was used to assess views and beliefs about medicines and participants individual perception of sensitivity to drug therapies.
Change in different classes of chronic back pain suspicious of axial spondyloarthritis: a latent transition analysis of the SPACE cohort.
RMD Open
September 2024
Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, Netherlands
Article Synopsis
- The study looked at four different groups of people with chronic back pain to see if their conditions changed over 2 years.
- They used information from doctors and tests to understand if people might switch from one group to another.
- After 2 years, the results showed that most people stayed in the same group, meaning it's unlikely for someone to suddenly develop new signs of their condition after being checked initially.
Article Synopsis
- - CCB toxicity poses a serious risk of death, making effective treatments like ECMO crucial; this study examines ELSO registry data to evaluate outcomes in adults with CCB toxicity treated with ECMO.
- - The research analyzed data from January 2016 to April 2023, focusing on factors like patient demographics and clinical indicators (e.g., pH levels) to determine mortality rates and predictors among those treated with ECMO.
- - Findings revealed a mortality rate of 40.6% for ECMO-treated patients, with severe acidosis and prior need for kidney treatment identified as significant mortality predictors; further studies are suggested to explore the impact of timely ECMO initiation.
: Cognitive impairment is a relevant problem in psychiatry and can be well assessed with a cross-diagnostic test such as the Screen for Cognitive Impairment in Psychiatry (SCIP). The aim of our pilot study is to assess cognitive impairment in acute psychiatric inpatients diagnosed with psychotic disorders, bipolar disorder and depression using the German version of the SCIP (SCIP-G). We also investigate whether cognitive dysfunction improves over the course of the inpatient treatment, where patients are offered a combination of pharmacological treatment and cognitive remediation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!